Rating Overview and Context
On 05 Feb 2026, MarketsMOJO revised Windlas Biotech Ltd’s rating from Hold to Sell, accompanied by a decline in its Mojo Score from 51 to 40. This adjustment reflects a reassessment of the company’s fundamentals, valuation, financial trends, and technical indicators. While the rating change date is crucial for understanding the timing of this evaluation, it is essential to consider the stock’s current data to gauge its present investment merit.
Here’s How Windlas Biotech Looks Today
As of 12 April 2026, Windlas Biotech remains a small-cap player in the Pharmaceuticals & Biotechnology sector, with a Mojo Grade firmly in the Sell category. The company’s stock price has shown mixed short-term movements, with a modest 1-month gain of 5.68% and a 3-month increase of 6.49%. However, longer-term performance remains weak, with a 6-month decline of 12.64% and a 1-year negative return of 10.80%, significantly underperforming the broader BSE500 index, which has delivered 9.24% over the same period.
Quality Assessment
Windlas Biotech’s quality grade is currently assessed as average. The company’s operating profit has grown at an annualised rate of 18.82% over the past five years, which, while positive, is considered modest within the pharmaceutical sector’s competitive landscape. The latest quarterly results for December 2025 reveal some concerns: profit after tax (PAT) stood at ₹15.00 crores, marking a decline of 10.9% compared to the previous four-quarter average. Additionally, cash and cash equivalents at ₹15.03 crores are at their lowest half-yearly level, and PBDIT for the quarter dropped to ₹24.38 crores, also a low point. These indicators suggest challenges in sustaining robust profitability and cash flow generation.
Valuation Perspective
The valuation grade for Windlas Biotech is deemed fair. While the stock’s current price does not appear excessively overvalued relative to its earnings and sector peers, the lack of strong growth momentum and subdued financial results limit its appeal. Investors should note that the company’s valuation does not offer a compelling margin of safety given the flat financial trend and the sector’s evolving dynamics.
Financial Trend Analysis
The financial trend for Windlas Biotech is classified as flat. The company’s recent quarterly performance indicates stagnation rather than growth, with key profitability metrics showing declines or minimal improvement. This flat trend is a critical factor in the current rating, as it signals limited upside potential in the near term. The absence of accelerating revenue or profit growth weighs on investor confidence and the stock’s attractiveness.
Technical Outlook
From a technical standpoint, the stock exhibits a mildly bearish pattern. Despite some short-term gains over the past month and quarter, the overall price trajectory remains subdued, with a slight negative movement of 0.16% on the most recent trading day. The technical indicators suggest caution, as the stock has not demonstrated sustained upward momentum or breakout signals that would support a more positive rating.
Implications for Investors
The Sell rating assigned by MarketsMOJO reflects a comprehensive evaluation of Windlas Biotech’s current fundamentals, valuation, financial trends, and technical signals. For investors, this rating implies that the stock is expected to underperform relative to the broader market and sector peers in the foreseeable future. The combination of average quality, fair valuation, flat financial trends, and mildly bearish technicals suggests limited potential for capital appreciation and increased risk exposure.
Investors should carefully consider these factors when assessing Windlas Biotech’s role in their portfolios. The current rating advises prudence and may warrant a reduction in exposure or avoidance until there is clear evidence of improvement in the company’s financial health and market positioning.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Summary and Outlook
In summary, Windlas Biotech Ltd’s current Sell rating by MarketsMOJO is grounded in a thorough analysis of its present-day financial and market conditions as of 12 April 2026. The company faces challenges in sustaining growth and profitability, reflected in its average quality grade and flat financial trend. Its valuation remains fair but does not compensate adequately for the risks posed by weak technical signals and underperformance relative to the market.
For investors seeking exposure to the Pharmaceuticals & Biotechnology sector, Windlas Biotech currently presents a cautious proposition. Monitoring future quarterly results and any strategic initiatives will be essential to reassess the stock’s potential. Until then, the Sell rating serves as a prudent guide to manage risk and capital allocation effectively.
Key Metrics at a Glance (As of 12 April 2026):
- Mojo Score: 40.0 (Sell Grade)
- 1-Year Stock Return: -10.80%
- BSE500 1-Year Return: +9.24%
- Operating Profit 5-Year CAGR: 18.82%
- Latest Quarterly PAT: ₹15.00 crores (-10.9% vs 4Q average)
- Cash & Cash Equivalents (Half Year): ₹15.03 crores (lowest level)
- Latest Quarterly PBDIT: ₹24.38 crores (lowest level)
Investors should weigh these figures carefully in the context of their portfolio objectives and risk tolerance.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
